Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

NewsGuard 100/100 Score

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the "Company"), today announces that it has increased the current private placement offering (the "Offering"), first reported on November 16, 2009, from a maximum of 3,846,154 units ("Units") to 4,335,500 Units, for total gross proceeds of up to $563,615. As previously announced, each Unit will be comprised of one common share of the Company (a "Share") and one half of one Share purchase warrant (a "Warrant"). Each whole Warrant will expire 18 months from the date the Warrant is issued (the "Expiry Date") and will entitle the holder to purchase one Share at a price of $0.17 per Share if purchased within 6 months from the date the Warrant is issued or $0.25 per Share if purchased after 6 months up to the Expiry Date.

Certain persons may assist the Company by introducing potential subscribers for the Offering and, subject to compliance with applicable legislation, will be entitled to receive a finder's fee, payable in cash and share purchase warrants, as permitted by law.

The net proceeds of the Offering will be used for the Company's research and development program and for working capital purposes.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study to test novel psychedelic compound as potential treatment for alcohol use disorder